Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)

NCT05286619 is registered in ClinicalTrials.gov with University of Malaya as lead sponsor.

NCT NCT05286619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05286619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
Lead sponsor
University of Malaya
Phase
Phase 2
Overall status
Recruiting
Start date
September 22, 2022
Completion date
December 31, 2028
Enrollment
63 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent/metastatic head and neck squamous cell carcinoma